Solara Medical Supplies Revenue and Competitors

Chula Vista, CA USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Solara Medical Supplies's estimated annual revenue is currently $48.6M per year.(i)
  • Solara Medical Supplies received $Undisclosed in venture funding in June 2018.
  • Solara Medical Supplies's estimated revenue per employee is $313,750

Employee Data

  • Solara Medical Supplies has 155 Employees.(i)
  • Solara Medical Supplies grew their employee count by 20% last year.

Solara Medical Supplies's People

NameTitleEmail/Phone
1
Director Customer Care OperationsReveal Email/Phone
2
Document Collection ManagerReveal Email/Phone
3
Sales DirectorReveal Email/Phone
4
Talent Acquisition SpecialistReveal Email/Phone
5
Insulin Pump and CGM specialistReveal Email/Phone
6
CUSTOMER SERVICE SPECIALISTReveal Email/Phone
7
Document Collection SpecialistReveal Email/Phone
8
Account Executive at Solara Medical Supplies/ AdapthealthReveal Email/Phone
9
Inside Sales RepresentativeReveal Email/Phone
10
Account ExecutiveReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.9M23-4%$271.3KN/A
Add Company

What Is Solara Medical Supplies?

Solara Medical Supplies has been proudly serving the diabetes community for over two decades. We service thousands of patients every year, nationwide and pride ourselves on providing personalized and caring service. We offer a great selection of specialized diabetes supplies at competitive prices on all the top brands. You can count on us for quality products, fast delivery, & superior service. We specialize in Insulin Pumps and Supplies, Testing Supplies, Continuous Glucose Monitors, and VED devices. We are a one-stop shop for all your diabetes needs. Our highly trained staff ensures fast and convenient home delivery anywhere in the country. You can easily find the supplies with the features you need at the fastest and most convenient way to order 24/7. By handling all of your paperwork, accepting Medicaid in most states, as well as most private and major medical insurance plans the ordering process is further simplified. Solara maximizes your benefits, helps minimize up-front/out-of-pocket expenses, and saves you money by working hard with your doctor and insurance provider. And we offer the most comprehensive coverage of any full-line, mail-order medical supply provider. With Solara it's Simple!

keywords:Biotechnology,Healthcare,Medical Devices

N/A

Total Funding

155

Number of Employees

$48.6M

Revenue (est)

20%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Solara Medical Supplies News

2022-04-20 - Proposed $5M settlement in Solara Medical lawsuit mandates ...

The diabetes medical supply vendor Solara Medical Supplies would perform specified remediation in a proposed settlement of a class-action...

2022-04-17 - Solara Medical Supplies to Pay $5 Million in Data Breach Deal

Solara Medical Supplies is on track to pay $5 million as part of a settlement with a group of individuals who claim that their personal and...

2018-12-10 - PE-backed Solara buys Pal-Med

Solara Medical Supplies, which is backed by Linden Capital Partners, has acquired South Carolina-based Pal-Med Inc, a direct-to-patient ...

2018-12-10 - Linden Capital-backed Solara Acquires Pal-Med

Solara Medical Supplies, a leading direct-to-patient supplier of advanced diabetic devices, including continuous glucose monitors, insulin pumps and other supplies for the intensively managed diabetic, announced today the acquisition of Pal-Med, Inc., a South Carolina-based direct-to-patient pro ...

2018-12-05 - Solara Medical Supplies Acquires Huey's Home Medical

(December 3, 2018)—Solara Medical Supplies (Solara), a direct-to-patient supplier of advanced diabetic devices, including continuous glucose ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$35M1659%N/A
#2
$41.9M2165%N/A
#3
$56.1M23247%N/A
#4
$80.8M27210%N/A
#5
$3.5M31653%N/A

Solara Medical Supplies Funding

DateAmountRoundLead InvestorsReference
2018-06-06$UndisclosedUndisclosedLinden Capital PartnersArticle